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Catalá-López et al.To the Editor—We thank Catalá-López and colleagues [1] for their
esponse to our article recently published in Value in Health and for
rawing our attention to their own recent work on the burden of
isease and drugs authorized by the European Medicines
gency between 1995 and 2009 [2,3], published outside the time
rame of our main literature search. In addition, they cite other
rticles focused on research funding and expenditure in rela-
ion to disease burden [4 –7]; however, this was not the focus of
ur study.
As Catalá-López and colleagues state, many of the technologies
e identified were coded as being indicated for “other” categories
ithin disease groups (e.g., “other malignant neoplasms”). It is
ot, however, true to say that these represent unspecified indica-
ions; all technologies included in “other” categories had specific
ndications associated with them. For instance, “other malignant
eoplasms” included rarer forms of cancer such as glioma, and
other digestive diseases” included Crohn’s disease. As we state,
echnologies with nonspecific indications were included only in
he second-level analyses (e.g., using broader headings such as all
malignant neoplasms”) but removed from the analysis at the
hird (individual disease) level. We acknowledged in our article
hat some categories would benefit from further subdivision; how-
ver, this does not imply that the disease categories were them-
elves ill-defined.
We do not therefore consider the alternative version of the
gure presented to be an appropriate representation of our find-
ngs. Excluding conditions classified within the “other” categories
mits a considerable proportion of the available data on individual
echnologies (representing real innovation). Our reported corre-
ation for the third-level analysis was calculated by using 102
ndividual specific disease categories for the identified technol-
gies, whereas the alternative figure uses just 18 of the highest
anking specific disease categories, creating an arbitrary data
et that does not provide a complete picture. Indeed our conclu-
ion that there is, at best, a weak association between innova-
ion and burden of disease corroborates Catalá-López and col-
eagues’ previous work [2] and agrees with their interpretation
of our own study data.
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